article thumbnail

Is prescribing anticancer drugs by body surface area still relevant?

Hospital Pharmacy Europe

The approach was adopted widely, particularly for cytotoxic chemotherapy agents, with the aim of standardising drug exposure and minimising toxicity. 5,6 Freireich et als work further validated this approach, showing that BSA correlated with drug efficacy and toxicity across several chemotherapy agents. 6 Gurney H.

article thumbnail

Six Biosimilars Part of EMA’s Authorization Recommendations in June

PharmTech

Zemcelpro is used to treat patients that require allogeneic hematopoietic stem cell transplantation following chemotherapy or radiotherapy when no other type of suitable donor cells is available. Two generic drugs were also approved.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ondansetron (Zofran) alternatives: What can I take instead?

The Checkup by Singlecare

but the generic version, ondansetron, is commonly prescribed for patients undergoing cancer treatments such as chemotherapy or radiation, or those who have recently undergone surgery. Aprepitant (Emend) is another, typically used for chemotherapy nausea. It’s typically taken as a capsule, with a dosage of anywhere from 80 to 125 mg.

article thumbnail

New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma

Pharmacy Times

Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.

FDA
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

A recent draft from the FDA provides valuable insight.

article thumbnail

Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using RWD

Pharmacy Times

A group of experts will present an encore abstract titled " Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using Real-World Data " at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20.

article thumbnail

The Value of a Medically Integrated Pharmacy to Maximize Cost Avoidance and Reduce Waste of Oral Oncolytic Medications

Pharmacy Times

Subscribe Now!